Introduction
This project was designed around structural understanding and pharmaceutical engineering of the Visfatin inhibitors. Visfatin being a fat produced insulin mimic may play a part in the initiation of Type 2 diabetes. Additionally, its interaction as an adipocytokine may be a factor in inflammatory damage in obese individuals. The understanding and limitation of Visfatin may help limit both Type 2 diabetes and inflammatory damage caused by Visfatin.
Specific and Overall Goal
The overall goal of this research is to investigate the interaction of multiple drug candidates to find the best drug candidates for targeted inhibition of Visfatin. This research will first determine the binding and chemical properties of the Visfatin active site molecules as a control group. Secondly, a group of select drug candidates whose properties are more effective at binding to the active site versus the control molecules will be chosen. Drug classification analysis will indicate preferences to improved active site binding. Finally, quantitative structure and activity relationship (QSAR) analysis will be done on both the control and experimental molecules to identify similar trends and values. Once found, similarities between these drugs will allow for a better understanding of the inhibition of Visfatin.
Experimental Methodology
1. The selection of 11 isoforms of Visfatin. 2. The screening and analysis of multiple drug candidates using IGemDock. 3. Similarity calculations were done to determine if molecular functionalities showed any preference to increased binding. 4. Selected candidates from IGemDock based on binding energy were tested using Dragon to determine structural similarities.
Methods and Materials
1172 structures were chosen which included, 715 FDA approved, 197 Alkaloids, 73 Imides, 40 Lactams, 36 Lactones, 50 NSAIDs, 25 Sulfanilamide and 37 Flavonoids pharmaceuticals were selected as ligands and computationally bound to 11 isoforms of the Visfatin protein using IGEMDock. IGEMDock used two independent docking with the average of both binding to factor in binding selectivity. An ANOVA was done to determine if any discrepancies in binding were seen between proteins. Additionally, grouping of the molecular functionalities were determine to find differences. The best 10 drug candidates on binding energies were selected and structural data such as molecular weight and partition coefficient was collected using Dragon. 3034. An ANOVA to determine differences between the critical value of 1.831. A search of the data indicates that 3DKL shows the greatest differences. Grouping analysis will be used to understand differences in protein active sites. 10 drugs were chosen due to their low binding energies (for both binding interactions). Structural analysis found that many of these molecules are small with similar partition coefficient (-0.009 to 3.174) of the top binders similar to that of the control molecules.
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Conclusion
By using the computational techniques we were able to identify several molecule that show improved binding efficacy over currently used Visfatin inhibitors. These Visfatin drug candidates indicated a diverse pool of Visfatin binders with improved efficacy. This work can be used to engineer these motifs into novel Visfatin inhibitors for improved drug efficacy.
